Fresenius SE SG&A Expenses 2016-2024 | FSNUY

Fresenius SE sg&a expenses for the twelve months ending June 30, 2024 were $1.679B, a 76.3% decline year-over-year.

  • Fresenius SE annual sg&a expenses for 2023 were $3.415B, a 51.94% decline from 2022.
  • Fresenius SE annual sg&a expenses for 2022 were $7.105B, a 10.14% increase from 2021.
  • Fresenius SE annual sg&a expenses for 2021 were $6.451B, a 4.01% increase from 2020.

Fresenius SE SG&A Expenses 2016-2024 | FSNUY

  • Fresenius SE annual sg&a expenses for 2023 were $3.415B, a 51.94% decline from 2022.
  • Fresenius SE annual sg&a expenses for 2022 were $7.105B, a 10.14% increase from 2021.
  • Fresenius SE annual sg&a expenses for 2021 were $6.451B, a 4.01% increase from 2020.
Related Stocks
Company NameMarket
Cap
Quest Diagnostics (DGX)$17.4B
DaVita (DVA)$12.3B
Encompass Health (EHC)$10.4B
Chemed (CHE)$8.3B
Elanco Animal Health (ELAN)$7.2B
RadNet (RDNT)$5.3B
Option Care Health (OPCH)$3.9B
Amedisys (AMED)$3.2B
LifeStance Health (LFST)$2.9B
Astrana Health (ASTH)$2.9B
Addus HomeCare (ADUS)$2.3B
U.S Physical Therapy (USPH)$1.4B
Pennant (PNTG)$1.1B
Aveanna Healthcare Holdings (AVAH)$1.1B
Atai Life Sciences (ATAI)$227M
Daxor (DXR)$45M
MEDIROM Healthcare Technologies (MRM)$14M
Psychemedics (PMD)$14M
ATI Physical Therapy (ATIP)$13M
Ontrak (OTRK)$8M
IMAC Holdings (BACK)$1M